通过抗血小板疗法减轻脑出血患者心血管事件负担 (BEAT-ICH)
通过抗血小板治疗减轻脑出血患者心血管事件的负担。
BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he/she will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.
研究概览
详细说明
Stroke is the second leading cause of death and disability globally. Intracerebral haemorrhage (ICH) accounts for 10% to 15% of strokes in high-income countries and 20% to 50% in developing countries. The proportion of ICH ranges from 19% to 41% in India and is higher in Eastern India. Recurrent stroke rates are high worldwide; 15% in India (Kolkata), 41% in China, 6 and 13% in Taiwan.
ICH patients are at a risk of recurrent stroke (ICH and ischaemic) and other serious cardiovascular events, and yet there is no consensus regarding starting antiplatelet drugs for secondary prevention. RESTART is the only trial (pilot) that studied antiplatelet therapy and showed a decrease in recurrent ICH compared to no antiplatelet therapy, with a median follow-up of 2 years (IQR [1·0-3·0]). The recurrence rates were 4% in the intervention group versus 9% in the control group. There is no large stroke trial which has addressed this question.
Hence, plan is to initiate the BEAT-ICH trial, a randomized placebo-controlled trial of ICH patients where intervention arm patients will receive antiplatelet monotherapy (Aspirin 75mg) and the control arm will receive a placebo. The primary outcome will be determining whether antiplatelet monotherapy provides a net reduction in major adverse cardiovascular and cerebrovascular events (MACE) in the long term in ICH patients.
Trial Population:
This multi-centric study will be conducted at 50 stroke centres in India associated with the INSTRuCT Network. All patients presenting with symptoms of stroke to the hospital and admitted to the stroke units will be screened for eligibility and if met, will be included in the study. The BEAT ICH trial intends to recruit 5676 patients.
Study design:
Each site will have a team of neurologists (Principal Investigator and Co-Investigators) and a site coordinator. All ICH patients admitted to stroke and neurology wards, Outpatient department (OPD) or Inpatient Department (IPD) after 24 hrs to 3 months will be screened for eligibility by the image-conformed haemorrhagic stroke by the site neurologist.
Investigators will collect complete information about patients' demographics, comorbidities, functional status (US National Institutes of Health Stroke Scale score (NIHSS) and the modified Rankin Scale mRS)), previous antithrombotic therapy, medical history, medication history (at the time of stroke and at the time of randomisation), and intracerebral haemorrhage (image confirmed), vitals and assessments and hematoma details into a database via a secure web interface with in-built validation to ensure complete baseline data before randomisation.
Each patient will undergo brain imaging by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) as part of routine care at the time of ICH before enrolment. In case of any events, a second CT/MRI scan will be performed to assess for haematoma. All images will be saved in Digital Imaging and Communications in Medicine (DICOM) format and uploaded to the trial's Picture Archiving and Communication System (PACS) server.
After obtaining the consent form, Data will initially be recorded on paper case record forms (pCRF) and later entered into the electronic database. Patients not meeting the trial's eligibility criteria (screen failures) will also be captured in the database. All the recruited patients will be covered under comprehensive insurance for the entire trial duration. Randomisation will be initiated ≥24 hours after ICH onset up to 3 months, provided ICH growth has stopped by 24 hours after onset, followed by the investigational product (Aspirin/placebo) for the entire trial duration. All patients will receive additional standard care as per current gulidelines along with the intervention. Patients in the intervention arm will receive Aspirin 75 mg daily, and the control arm will receive a placebo tablet of similar shape, size, and colour daily. Both investigational products will be pills that look similar in appearance. Pharmaceutical company will centrally manufacture, label, and dispense the investigational products under the supervision of the pharmacologist at Christian Medical College and Hospital (CMCL). Since this trial is triple-blinded, the investigator, coordinator, and patient will be blinded to the allocated study treatment. Only the pharmacologist will decode in case of an event requiring a medication change in an emergency.
Each site will have a stock for a duration of one year, with new investigational products delivered yearly or based on prior consumption and follow-up requirements. Each site is expected to have a dedicated IP room for this purpose. Once delivered, the site will handle the storage, dispensing, and destruction of the investigational products, unused IP, and returned kits under the hospital's waste disposal management protocols with strict supervision.
The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he/she will take the medication for six months and be followed up for the same duration. The trial's total duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.
All patients will remain in the trial until the end of the study period (3 years to the max)/event/death/withdrawal. If a patient develops an event, the investigational product will be stopped, and treatment will be initiated based on the event and clinical guidelines. Unused investigational products will be returned to the site. If required, the trial pharmacologist will handle decoding after an event. Site research staff will capture all event-related data and submit it to the database and the site ethics committee for review. The central independent event adjudication committee will also review this data. In case of patient withdrawal or death, the investigational product will also be returned to the site. All patients will be analysed using the intention-to-treat principle, even if they withdraw at any point during the trial.
Patients will be called for face-to-face visits every 3 months to dispense the investigational product. Kits will be labelled as BEAT-ICH trial medication, with a unique kit number for identification for each patient. Each kit will contain 100 tablets, including a buffer of 10 tablets for delayed visits/buffer dose. The site coordinators will call the patient 15 days before the visit as a reminder to come to the hospital to take the next batch of IP. Monthly telephonic follow-ups will ensure medication adherence and detect events. Patients will be encouraged to report events during the interim follow-up period. At each visit, patients will return used kits and unused medication (expected return of approximately 10 tablets on every three-month visit) to monitor medication adherence.
The need for this study:
The BEAT-ICH trial has the potential to reduce the recurrent stroke rate and MACE after ICH. In addition, this trial will address the important question of the safety of antiplatelet use in ICH patients. If completed, this trial can change Clinical practice and guidelines globally, as aspirin is a low-cost drug that can be provided at all levels of healthcare in India.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Jeyaraj D Pandian, MD, DM
- 电话号码:+919915784750
- 邮箱:jeyarajpandian@hotmail.com
研究联系人备份
- 姓名:Deepti Arora, BHMS, MSc
- 电话号码:+917837764718
- 邮箱:dr.deepti7@yahoo.com
学习地点
-
-
-
Delhi、印度、110054
- 招聘中
- St Stephen's Hospital
-
接触:
- Gaurav K Mittal, MD DM
- 电话号码:7042877975
- 邮箱:drgkmittal@gmail.com
-
首席研究员:
- Gaurav K Mittal, MD DM
-
Guwahati、印度、781101
- 招聘中
- All India Institute of Medical Science
-
接触:
- Masaraf Hussain, MD DM
- 电话号码:8414090873
- 邮箱:masarafhussain@aiimsguwahati.ac.in
-
首席研究员:
- Masaraf Hussain, MD DM
-
Hyderabad、印度、500016
- 招聘中
- KIMS-Sunshine Hospitals
-
接触:
- Shyam K Jaiswal, MD DNB
- 电话号码:7416848385
- 邮箱:drshyamjaiswalneuro@gmail.com
-
首席研究员:
- Shyam K Jaiswal, MD DNB
-
Hyderabad、印度、500034
- 招聘中
- Renova Institute of Neurological Sciences (RINS); Renova Century Hospital
-
接触:
- Y Muralidhar Reddy, MD DM
- 电话号码:9912329342
- 邮箱:muralidharnims@gmail.com
-
首席研究员:
- Y Muralidhar Reddy, MD DM
-
Lucknow、印度、226014
- 招聘中
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
-
接触:
- Vinita E Mani, MD DM
- 电话号码:8004966335
- 邮箱:vinita.daniel@gmail.com
-
首席研究员:
- Vinita E Mani, MD DM
-
New Delhi、印度、110029
- 招聘中
- All India Institute of Medical Science
-
接触:
- Ayush Agarwal, MD DM
- 电话号码:8193900444
- 邮箱:dr.agarwal.ayush@gmail.com
-
首席研究员:
- Ayush Agarwal, MD DM
-
-
Andhra Pradesh
-
Guntur、Andhra Pradesh、印度、522001
- 招聘中
- Government General Hospital
-
接触:
- G Binod, MD DM
- 电话号码:8099033844
- 邮箱:bindunarmadagottipati@gmail.com
-
首席研究员:
- G Binod, MD DM
-
Guntur、Andhra Pradesh、印度、522001
- 招聘中
- Lalitha Super Specialty Hospital
-
接触:
- Vijaya Pamidimukkala, MD DM
- 电话号码:9440808621
- 邮箱:drvijayapvr@gmail.com
-
首席研究员:
- Vijaya Pamidimukkala, MD DM
-
Guntur、Andhra Pradesh、印度、522004
- 招聘中
- Dr Ramesh Cardiac and Multispecialty Hospital
-
接触:
- Somasundaram Kumaravelu, MD DM
- 电话号码:9553651777
- 邮箱:neurovelu@gmail.com
-
首席研究员:
- Somasundaram Kumaravelu, MD DM
-
Kākināda、Andhra Pradesh、印度、533003
- 招聘中
- Government General Hospital
-
接触:
- Raviteja kakarla, MD DM
- 电话号码:9989798599
- 邮箱:kravicharles1988@gmail.com
-
首席研究员:
- Raviteja kakarla, MD DM
-
Nellore、Andhra Pradesh、印度、524003
- 招聘中
- Narayana Medical College and Hospital
-
接触:
- N S Sampath, MBBS DNB MD
- 电话号码:9849959527
- 邮箱:drnssampath123@gmail.com
-
首席研究员:
- N S Sampath, MBBS DNB MD
-
-
Assam
-
Guwahati、Assam、印度、781033
- 招聘中
- Apollo Excelcare Hospitals
-
接触:
- Lakshya J Basumatary, MD DM
- 电话号码:9954480668
- 邮箱:drbasumatary@gmail.com
-
首席研究员:
- Lakshya J Basumatary, MD DM
-
Tezpur、Assam、印度、784001
- 招聘中
- Baptist Christian Hospital
-
接触:
- Jacob Johnson, MD
- 电话号码:7598626847
- 邮箱:cooljacky44@gmail.com
-
首席研究员:
- Jacob Johnson, MD
-
-
Bihar
-
Patna、Bihar、印度、801507
- 招聘中
- All India Institute of Medical Science
-
接触:
- Pratibha Prasad, MD DM
- 电话号码:9653010125
- 邮箱:pratibhaaiims12@gmail.com
-
首席研究员:
- Pratibha Prasad, MD DM
-
-
Jharkhand
-
Ranchi、Jharkhand、印度、834009
- 招聘中
- Rajendra Institute of Medical Sciences
-
接触:
- Surendra Kumar, MD DM
- 电话号码:8004298980
- 邮箱:sksurindar770@gmail.com
-
首席研究员:
- Surendra Kumar, MD DM
-
-
Karnataka
-
Belagavi、Karnataka、印度、590010
- 招聘中
- KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre
-
接触:
- Aralikatte O Saroja, MD DM
- 电话号码:9448468474
- 邮箱:sarojaao2002@yahoo.com
-
首席研究员:
- Aralikatte O Saroja, MD DM
-
-
Kerala
-
Kochi、Kerala、印度、682041
- 招聘中
- Amrita Institute for Medical Sciences and Research Center
-
接触:
- Vivek K Nambiar, MD DM
- 电话号码:8921485541
- 邮箱:vivek19602@aims.amrita.edu
-
首席研究员:
- Vivek K Nambiar, MD DM
-
Thiruvananthapuram、Kerala、印度、695011
- 招聘中
- Government Medical College Trivandrum
-
接触:
- Chithra P, MD DNB
- 电话号码:9495202065
- 邮箱:drchithrap5@gmail.com
-
首席研究员:
- Chithra P, MD DNB
-
Thiruvananthapuram、Kerala、印度、695011
- 招聘中
- Sree Chitra Tirunal Institute for Medical Sciences and Technology
-
接触:
- Padmavathyamma N Sylaja, MD DM
- 电话号码:9446566287
- 邮箱:sylajapn@hotmail.com
-
首席研究员:
- Padmavathyamma N Sylaja, MD DM
-
-
Maharashtra
-
Mumbai、Maharashtra、印度、400016
- 招聘中
- P. D. Hinduja Hospital and Medical Research Centre
-
首席研究员:
- Darshan Doshi, MD DM
-
接触:
- Darshan Doshi, MD DM
- 电话号码:9845633469
- 邮箱:DARSHANKDOSHI@GMAIL.COM
-
Pune、Maharashtra、印度、411043
- 招聘中
- Bharati Vidyapeeth DTU Medical College
-
接触:
- Sankar P Gorthi, MD DM
- 电话号码:8800233991
- 邮箱:pgorthi2002@yahoo.com
-
首席研究员:
- Sankar P Gorthi, MD DM
-
-
National Capital Territory of Delhi
-
New Delhi、National Capital Territory of Delhi、印度、110095
- 招聘中
- Institute of Human Behaviour and Allied Sciences
-
接触:
- Rajinder K Dhamija, MD DNB
- 电话号码:99908 86679
- 邮箱:director@ihbas.org
-
首席研究员:
- Rajinder K Dhamija, MD DNB
-
-
Odisha
-
Bhubaneswar、Odisha、印度、751019
- 招聘中
- All India Institute of Medical Sciences
-
接触:
- Sanjeev K Bhoi, MD DM
- 电话号码:+91 9919787978
- 邮箱:sanjeev_bhoi@rediffmail.com
-
首席研究员:
- Sanjeev K Bhoi, MD DM
-
-
Punjab
-
Farīdkot、Punjab、印度、151203
- 招聘中
- Guru Gobind Singh Medical College and Hospital
-
接触:
- Sulena Sulena, MD DM
- 电话号码:7087907025
- 邮箱:sulenasingh@yahoo.co.in
-
首席研究员:
- Sulena Sulena, MD DM
-
-
Rajasthan
-
Bikaner、Rajasthan、印度、334001
- 招聘中
- PBM Hospital
-
接触:
- Inder Puri, MD DM
- 电话号码:7023266560
- 邮箱:dr.inderpuri@gmail.com
-
首席研究员:
- Inder Puri, MD DM
-
Jaipur、Rajasthan、印度、302015
- 招聘中
- Santokba Durlabhji Memorial Hospital
-
接触:
- Neeraj Bhutani, DM
- 电话号码:98287 11808
- 邮箱:drneerajbhutani@rediffmail.com
-
首席研究员:
- Neeraj Bhutani, DM
-
Kota、Rajasthan、印度、324005
- 招聘中
- Jaiswal Hospital and Neuro Institute
-
接触:
- Sanjay Jaiswal, MD DM
- 电话号码:9414183889
- 邮箱:drsjaiswal@gmail.com
-
首席研究员:
- Sanjay Jaiswal, MD DM
-
-
Tamil Nadu
-
Coimbatore、Tamil Nadu、印度、641018
- 招聘中
- KG Hospital and Post Graduate Medical Institute Coimbatore
-
接触:
- TCR Ramakrishnan, MD DM
- 电话号码:9443365792
- 邮箱:kgneuro@gmail.com
-
首席研究员:
- TCR Ramakrishnan, MD DM
-
Vellore、Tamil Nadu、印度、632517
- 招聘中
- Christian Medical College Vellore
-
接触:
- Deepti Bal, DM
- 电话号码:9003573111
- 邮箱:dr.deeptibal@gmail.com
-
首席研究员:
- Deepti Bal, DM
-
-
Uttar Pradesh
-
Lucknow、Uttar Pradesh、印度、226003
- 招聘中
- King George's Medical University
-
接触:
- Harish Nigam, MD DM
- 电话号码:7651960944
- 邮箱:harish.nigam007@gmail.com
-
首席研究员:
- Harish Nigam, MD DM
-
Raebareli、Uttar Pradesh、印度、229405
- 招聘中
- All India Institute of Medical Sciences
-
接触:
- Archana Verma, MD DM
- 电话号码:9415618867
- 邮箱:archanashiva2010@rediffmail.com
-
首席研究员:
- Archana Verma, MD DM
-
Varanasi、Uttar Pradesh、印度、221005
- 招聘中
- Institute of Medical Sciences of the Banaras Hindu University (BHU)
-
接触:
- Abhishek Pathak, MD DM
- 电话号码:8948512666
- 邮箱:abhishekpathakaiims@gmail.com
-
首席研究员:
- Abhishek Pathak, MD DM
-
-
West Bengal
-
Kolkata、West Bengal、印度、700020
- 招聘中
- Bangur Institute of Neurosciences
-
接触:
- Biman K Ray, MD DM
- 电话号码:9433185327
- 邮箱:biman.kanti@rediffmail.com
-
首席研究员:
- Biman K Ray, MD DM
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years
- First-ever Intracerebral Haemorrhage
- Presenting ≥24 hrs up to 3 months of stroke symptoms confirmed by brain imaging
- CT /MRI confirming Intracerebral Haemorrhage
- Alive ≥24 hours after non-traumatic ICH
Exclusion Criteria:
- ICH is known to be due to trauma, a structural cause (e.g., aneurysm, arteriovenous malformation, cerebral cavernous malformation, venous thrombosis, or tumour), or haemorrhagic transformation of cerebral infarction
- Glasgow coma score ≤5
- Taking any antiplatelet or anticoagulant therapy 15 days prior to randomization.
- Women pregnant, breastfeeding, childbearing potential, and not using contraceptives
- Enrolled in any other clinical trial
- Sick or compromised patients with life expectancy of less than a year
- Geographical or other factors that prohibit long-term follow-up
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Aspirin 75 mg OD
The intervention is oral daily Aspirin 75 mg OD (antiplatelet drug monotherapy) in addition to standard care for secondary prevention after ICH based on the universal guidelines. |
The intervention is oral daily Aspirin 75 mg OD The duration of the medication and follow-up will vary based on the recruitment timeline. If recruited during the first year of the trial, the first patient will take the medication for 2.5 years, and the last patient will get the IP for a minimum of 6 months.
其他名称:
|
|
安慰剂比较:Placebo
The control arm is placebo, which will be look-alike both as kits and tablets and will be prescribed in the same way as Aspirin: OD along with the standard secondary prevention after ICH. |
The intervention is a placebo to be taken OD. The duration of the placebo and follow-up will vary based on the recruitment timeline. If recruited during the first year of the trial, the first patient will take the placebo for 2.5 years, and the last patient will get the placebo for a minimum of 6 months.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major Adverse Cardiovascular Events (MACE)
大体时间:3 years
|
To reduce the risk of first MACE (stroke, myocardial infarction, hospitalisation, or death) with antiplatelet monotherapy in ICH patients. The components of the MACE include ischemic stroke, haemorrhagic stroke, hospitalisation due to stroke (ischemic, haemorrhagic, subarachnoid haemorrhage), myocardial infarction, coronary artery disease, cerebral and cardiovascular death due to any vascular causes (including pulmonary embolism, gastrointestinal haemorrhage) or death due to non-Cerebrovascular and cardiovascular causes. |
3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major bleeding
大体时间:3 years
|
To study the safety composite outcome of major bleeding (all major haemorrhagic events that are fatal or result in hospitalisation) |
3 years
|
|
Medication adherence
大体时间:3 years (every 3 months) till study end
|
To check the adherence of aspirin vs placebo. |
3 years (every 3 months) till study end
|
|
modified Rankin Scale
大体时间:3 years (every 3 months) till study end
|
To check the modified Rankin Scale (mRS), a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a ICH stroke. |
3 years (every 3 months) till study end
|
合作者和调查者
合作者
调查人员
- 首席研究员:Jeyaraj D Pandian, MD, DM、Christian Medical College and Hospital, Ludhiana, Punjab, India
出版物和有用的链接
一般刊物
- Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018 Apr;38(2):208-211. doi: 10.1055/s-0038-1649503. Epub 2018 May 23.
- RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet. 2019 Jun 29;393(10191):2613-2623. doi: 10.1016/S0140-6736(19)30840-2. Epub 2019 May 22.
- Wong YS, Tsai CF, Ong CT. Risk factors for stroke recurrence in patients with hemorrhagic stroke. Sci Rep. 2022 Oct 13;12(1):17151. doi: 10.1038/s41598-022-22090-7.
- Banerjee TK, Das SK. Fifty years of stroke researches in India. Ann Indian Acad Neurol. 2016 Jan-Mar;19(1):1-8. doi: 10.4103/0972-2327.168631.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BEAT ICH
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All information collected from medical records for the study will be stored electronically in a specifically designed database at the Christian Medical College and Hospital, Ludhiana, Punjab, India. Participants information will be identified only by their initials and a study registration number. Any information transferred electronically will be coded to protect confidentiality. All computer records will be password-protected. The study results may be presented at conferences or in scientific publications, but individual participants will not be identifiable. If needed, data will be available in future for other researchers outside the primary research group for secondary purposes, such as metaanalyses, reanalysis, or replication of results.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.